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Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Yasser R. Abou Mourad,
Julye C. Lavoie, Michael J. Barnett, Stephen H. Nantel, Cynthia L. Toze, Donna E. Hogge,
Donna L. Forrest, Kevin W. Song, Maryse M. Power, Janet Y. Nitta,
Yunfeng Dai, Clayton A. SmithThe optimal therapy for myelodysplastic syndrome (MDS) is allogeneic bone marrow (BM) or blood (BSC)
stem cell transplantation (SCT), although outcomes are limited by nonrelapse mortality (NRM) and relapse.
A retrospective review was performed of 156 patients who underwent SCT (114 BM, 42 BSC) for MDS or
secondary acute myelogenous leukemia (sAML) at our institution. Fifty-five patients remain in continuous
complete remission: 35 BM recipients and 20 BSC recipients (median follow-up 139 and 89 months, respec-
tively). Estimated 7-year event-free survival (EFS), NRM, and risk of relapse (ROR) are 33% (95% confidence
intervals [CI] 25%-43%), 42% (CI 33%-51%), and 25% (CI 17%-33%) for the BM cohort and 45% (CI 32%-
64%, P 5 .07), 32% (CI 18%-47%, P 5 .15), and 23% (CI 11%-37%, P 5 .79) for the BSC cohort. Multivariate
analysis showed IPSS poor-risk cytogenetics (P\.001), time from diagnosis to SCT (P\.001), FAB subgroup
(P5.001), recipients not in complete remission (CR1) at SCT (P5.005), and the development of acute graft-
versus-host disease (aGVHD) (P 5 .04) were all predictive of an inferior EFS. The FAB subgroup (P5 .002),
poor-risk karyotype (P 5 .004), and non-CR1 status also correlated with ROR in multivariate analysis.
EFS for poor-risk karyotype patients was superior after receiving BSC compared to BM (39% versus 6%,
P\.001). SCToutcomes in MDS/sAML are strongly associated with the IPSS cytogenetic risk group, although
the use of BSC in poor-risk karyotype patients may lead to a more favorable long-term EFS.
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Myelodysplastic syndrome (MDS) is a hematopoi-
etic stem cell disorder that may be familial, de novo
(primary), or chemotherapy and/or radiation induced
(therapy-related). MDS is characterized by variable
anemia, neutropenia, and thrombocytopenia, and has
a high propensity to evolve into secondary acute mye-
loid leukemia (sAML) [1]. The treatment that has con-The Leukemia/BMT Program of British Columbia, Divi-
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6/j.bbmt.2008.11.015sistently resulted in long-term survival for patients
with MDS/sAML is allogeneic stem cell transplanta-
tion (SCT). However, numerous studies have reported
that SCT outcomes for MDS/sAML patients are lim-
ited by relatively high rates of relapse and nonrelapse
mortality (NRM) [2-7]. Although NRM is similar
among all MDS/sAML cytogenetic risk groups, high
relapse rates have been a particular issue for patients
with a poor-risk karyotype [5,8].
In the mid-1990s, transplantation centers began to
study the use of granulocyte colony stimulating factor
(G-CSF)-mobilized blood as a source of allogeneic
stem cells. Early reports suggested that engraftment
was hastened with blood stem cells (BSC) when
compared to bone marrow (BM) cells, resulting in
a reduction in NRM [9-11]. Subsequently, a large ret-
rospective registry analysis [12] and 3 randomized
studies [13-15] comparing the 2 stem cell sources
confirmed the more rapid engraftment and the reduc-
tion in NRM, particularly in high-risk patients. As
a consequence, individuals in the high-risk cohort,
including those patients with MDS, had a superior205
206 Biol Blood Marrow Transplant 15:205-213, 2009T. J. Nevill et al.survival when BSC were used. However, there re-
mained a concern that the use of G-CSF-mobilized
BSC could increase the risk of chronic graft-versus-
host disease (cGVHD) [12,16,17]. As a result, BSC
have been used less frequently for nonmalignant con-
ditions and in the pediatric SCT setting in general.
Furthermore, there has been some trepidation regard-
ing the potential risks of using G-CSF-mobilized BSC
in volunteer unrelated donor SCT [18,19]. In this anal-
ysis of our 20-year institutional experience, the results
of BM and BSC transplantation for patients with
MDS/sAMLwere retrospectively compared, with par-
ticular attention given to the outcomes observed in pa-
tients with a poor-risk karyotype.
PATIENTS AND METHODS
Patient characteristics
Between June 1985 and March 2007, 156 patients
underwent allogeneic SCT for primary or therapy-
related MDS/sAML at Vancouver General Hospital.
One hundred fourteen patients received BM stem cells
and 42 patients received G-CSF-mobilized BSC. Pa-
tient characteristics for the 2 groups are shown in
Table 1. All patients provided informed consent, and
all research studies were approved by the University
and institutional review boards. BM histopathology
was centrally reviewed. Given that the initial 102 pa-
tients underwent SCT prior to the publication of the
World Health Organization (WHO) Classification
of Neoplastic Diseases of the Hematopoietic and
Lymphoid Tissues in December 1999, all patients in
the analysis were classified according to standard
FAB criteria [20]. As per institutional policy [5], con-
ventional cytoreductive chemotherapy (high-doseTable 1. Patient Characteristics
Bone Marrow
SCT n 5 114 (%)
Blood SCT*
n 5 42 (%) P Value
Median age at SCT,
years [range]
40 [15-55] 48 [17-55] .02
Sex, M/F 55/59 20/22 .79
Diagnosis
RA/RARS/CMML 25 (22) 15 (36)
RAEB 18 (16) 13 (31) .01
RAEBIT/sAML 71 (62) 14 (33)
Therapy-related disease 14 (12) 9 (20) .39
IPSS cytogenetic group
Good risk 45 (39) 14 (33)
Intermediate risk 34 (30) 11 (26) .48
Poor risk 33 (29) 17 (40)
Failed 2 (2) —
Median time Dx/SCT, [range] 2.8 [0.2-100] 3.5 [0.5-62] .05
SCT indicates stem cell transplantation; M, male; F, female; RA, refrac-
tory anemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess
blasts; RAEBIT, RAEB in transition; CMML, chronic myelomonocytic leu-
kemia; sAML, secondary acute myelogenous leukemia; IPSS, Interna-
tional Prognostic Scoring System; Dx, diagnosis; mos, months.
*Includes 3 patients who received both bone marrow and blood stem
cells.cytosine arabinoside and daunorubicin or mitoxan-
trone with or without etoposide) was administered
only when required for hematologic stabilization while
tissue typing of potential donors was being completed
(48 patients, 31% of the cohort).
Selection of Patients and Stem Cell Source
Patients with MDS were considered for SCT if
they had satisfactory major organ function and at least
1 of the following: (1) therapy-relatedMDS/sAML, (2)
life-threatening neutropenia or thrombocytopenia, (3)
increased blast count in the blood and/or BM,
(4) IPSS intermediate- or poor-risk clonal cytogenetic
abnormalities, or (5) evidence of incipient organ dam-
age because of transfusional iron overload. BM was
used as the exclusive stem cell source until September
1996, when patients were randomized to receive either
BMorG-CSF-mobilized BSC as part of a separate Ca-
nadian Bone Marrow Transplant Group (CBMTG)
study [15]. Eight patients on the CBMTG study had
BSC collected from a sibling donor by apheresis for
2 consecutive days following administration of 5 mg/
kg/day of G-CSF subcutaneously for 4 days. Three
of the 8 donors had a yield of CD341 cells of\2.5 
106/kg recipient weight and, as per protocol, also un-
derwent BM harvest. In each case, recipients were
given both stem cell products, although, for the pur-
pose of analysis, these 3 patients were included in the
BSC group. After consideration of emerging data
from centers using blood cells for unrelated donor
SCT [21], our institution adopted a policy, in June
2000, of requesting, whenever possible, G-CSF-mobi-
lized BSC for unrelated donor SCT. Finally, based
upon the preliminary results from the CBMTG study
(closed to accrual in February 2000), GCSF-mobilized
BSC became the standard for sibling donor SCT for
MDS/sAML in January 2002. Beginning in June
2000, the G-CSF dose used for all allogeneic donors
was 10 mg/kg/day subcutaneously.
Cytogenetics
Cytogenetic analyses were performed on direct
and/or unstimulated cultured marrow specimens at 4
reference laboratories and reviewed at Vancouver
General Hospital. All patients in this report had BM
karyotyping done prior to SCT, and specimens from
all but 2 patients (both in the BM SCT group) yielded
analyzable metaphases. Patients were divided into
prognostic cytogenetic subgroups according to ac-
cepted IPSS criteria [22]. In brief, good-risk patients
were those with normal karyotypes, -Y alone, del(5q)
alone, or del(20q) alone. Poor-risk patients were those
with abnormalities involving chromosome 7 or those
with a complex karyotype ($3 unassociated abnormal-
ities). All remaining patients were considered interme-
diate-risk.
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Transplantation details for the BM and BSC
groups are shown in Table 2. Donor and recipient his-
tocompatibility testing was performed serologically at
theHLA-A, B, andDR loci for the initial 40 SCT pairs
in the study, including 10 unrelated SCT pairs. The fi-
nal 44 donor/recipient pairs in the study had HLA
class I and II testing performed with DNA-based tech-
niques. All others (68 donor/recipient pairs) had class I
serologic typing and high-resolution DNA-based DR
testing done. Conditioning regimens were all myeloa-
blative, with doses based upon the lesser of actual or
ideal body weight. In the 2 weeks prior to SCT, a lum-
bar puncture was routinely performed with instillation
of cytosine arabinoside 30 mg/m2. In general, total
body irradiation (TBI) was used prior to unrelated do-
nor SCT (prior radiotherapy exposure precluded its
use in 4 such recipients) and busulfan (Bu)-based pre-
parative regimens were used prior to related-
donor SCT. Oral Bu was used until February 2004,
when i.v. Bu was introduced for the final 11 non-TBI
patients. Supportive care has previously been de-
scribed in detail [5]. In brief, all patients were treated
in rooms equipped with high-efficiency particulate
air (HEPA) filtration. Patients receiving high-dose
Bu were given phenytoin as seizure prophylaxis [23],
and standard uroepithelial prophylaxis was hyperhy-
dration (3 L/m2/day) with or without mesna [24]. He-
patic venooclusive disease prophylaxis with low-dose
i.v. heparin [25] was given to the final 116 patients in
the study group. During the period of the study,
GVHD prophylaxis varied according to center policyTable 2. Transplantation Characteristics
Bone Marrow
SCT n 5 114 (%)
Blood SCT*
n 5 42 (%) P Value
Disease status
at SCT
Untreated 75 (66) 33 (79)
CR1 17 (15) 7 (17) .78
Relapsed/refractory 22 (19) 2 (5)
Donor source
Related 62 (54) 26 (62)
Matched 60 25
Mismatched 2 1 .40
Unrelated 52 (46) 16 (38)
Matched 41 11
Mismatched 11 5
Conditioning
Busulfan-based 65 (57) 27 (64) .40
TBI-based 49 (43) 15 (36)
GVHD prophylaxis
CSA/MTX 91 (80) 42 (100)
CSA/TCD 11 (10) — .03
Other 12 (11) —
SCT indicates stem cell transplantation; CR1, first complete remission;
TBI, total body irradiation; GVHD, graft-versus-host disease; CSA,
cyclosporine; MTX, methotrexate; TCD, T cell depletion.
*Includes 3 patients who received both bone marrow and blood stem
cells.at the time, but the vast majority of patients received
standard continuous infusion CsA and short-course
MTX [26]. A T cell depletion protocol using anti-
CD3 antibodies was used in 11 BM SCT patients
between October 1993 and September 1995 [27].
Acute GVHD (aGVHD) and cGVHD were graded
according to standard criteria [28,29]. Treatment of
established aGVHD was with high-dose methylpred-
nisolone (MP); those resistant to MP received 1 of
the following anti-T cell antibodies: anti-CD5/ricin
immunotoxin (XomaZyme; XOMA Corp, Berkeley,
CA), interleukin-2 receptor antibody (either BT563;
Biotest, Dreieich, Germany, or Daclizumab, Roche
Pharmaceuticals, Nutley, NJ) or antithymocyte globu-
lin (ATG) (either ATGAM, Upjohn, Kalamazoo, MI,
or Thymoglobulin, Genzyme Corp, Cambridge, MA).
Statistical Methods
Event-free survival (EFS) and actuarial risk of
aGVHD and cGVHD was determined by the Ka-
plan-Meier method [30]. Risk of relapse (ROR) and
nonrelapse mortality (NRM) were calculated using
a competing risks technique [31]. Patient and trans-
plantation characteristics in the BM and BSC cohorts
were compared using the 2-sample t-test (for continu-
ous variables), the chi-square test, or the Fisher’s exact
test. With respect to the entire 156 patient cohort,
prognostic factors potentially influencing EFS,
NRM, and ROR that were analyzed included: age at
SCT and disease duration (both as continuous vari-
ables), sex, FAB diagnosis stem cell source (BSC versus
BM), IPSS cytogenetic risk group (good/intermediate-
risk versus poor-risk), disease status (CR1 versus
other), donor type (related versus unrelated), year of
SCT, development of aGVHD and cGVHD, and con-
ditioning regimen (Bu versus TBI based). As time-de-
pendent covariates, aGVHD and cGVHD were not
included in the NRM and ROR competing risk analy-
ses, as previously described [32]. In a separate analysis,
the EFS, ROR, and NRM for patients that underwent
BM and BSC transplantation were compared for each
of 2 IPSS cytogenetic risk groups: good/intermediate-
risk and poor-risk. Univariate and multivariate
analyses of prognostic factors were performed using
a proportional hazards Cox regression model [33].RESULTS
Survival
Fifty-five patients remain alive and in a continuous
complete remission (CCR), with a median follow-up
of 108 months (range: 8-227 months). The estimated
7-year EFS for the entire group was 36% (confidence
interval [CI] 29%-45%). Of the 114 patients who un-
derwent BMSCT, 35 patients remain in CCR (median
follow-up 139 months) with estimated 7-year EFS
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Figure 2. NRM following allogeneic BM (n 5 114) and blood (PB,
n 5 42) SCT for patients with MDS/sAML.
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tient who experienced marrow graft failure 6 months
following matched sibling SCT and became a long-
term survivor after receiving BSC from the same do-
nor. Twenty of 42 BSC transplantation patients re-
main in CCR (median follow-up 89 months) with
estimated 7-year EFS being 45% (CI 32%-64%)
(P 5 .07, when compared to bone marrow SCT pa-
tients). EFS according to stem cell source is shown in
Figure 1.
GVHD
The cumulative risk of aGVHD for the entire co-
hort was 60% (CI 52%-67%). There was no difference
in risk of aGVHD between BM SCT patients (61%)
and patients who received BSC (57%, P 5 .63). The
cumulative risk of cGVHD was 87% (CI 76%-93%)
for the entire cohort, with risk being similar following
BSC (90%) and BM (84%) transplantation (P 5 .30).
NRM
Sixty-four patients died of NRM (7-year actuarial
risk 39%; CI 32%-47%), including 51 patients follow-
ing BMSCT and 13 patients following BSC transplan-
tation. The risk of NRM was 42% (CI 33%-51%) for
the BM cohort and 32% (CI 18%-47%, P 5 .15) for
the BSC cohort (Figure 2). Causes of NRM included
aGVHD (BM: 17 patients; BSC: 3 patients), cGVHD
(BM: 12 patients; BSC: 6 patients), opportunistic in-
fection (BM: 7 patients; BSC: 1 patient), regimen-
related organ toxicity (BM: 6 patients; BSC 1 patient),
primary graft failure (BM: 4 patients; BSC: 1 patient),
and thrombocytopenic hemorrhage (3 BM patients).
One patient died of pulmonary embolism 3 years post-
sibling BM SCT and 1 patient died of a second malig-
nancy (lung carcinoma) 7 years after unrelated donor
BM SCT.0 5 10 15
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Years
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
e
v
e
n
t
-
f
r
e
e
 
s
u
r
v
i
v
a
l
PB
BM
Plog-rank = 0.07 
Figure 1. EFS following allogeneic BM (n5 114) and blood (PB, n5 42)
SCT for patients with MDS/sAML.Relapse
Thirty-seven patients relapsed following SCT (7-
year actuarial ROR 24%; CI 17%-31%), including 28
BM patients and 9 BSC patients. The ROR for the
BM cohort was 25% (CI 17%-33%) and for the BSC
cohort was 23% (CI 11%-37%, P 5 .79). Survival fol-
lowing relapsewas typically short (medianof 3months),
and none of the patients that relapsed survived.
Prognostic Factors for EFS
Univariate analysis revealed that interval from di-
agnosis to SCT (P5 .01), IPSS poor-risk cytogenetics
(P5 .001), non-CR1 status at SCT (P5 .004), and the
development of aGVHD (P5 .02) were all significant
predictors of an inferior EFS (Table 3). Multivariate
analysis (Table 4) showed that all of these factors re-
mained significant and, in addition, the FAB subgroup
was a predictor of EFS (Figure 3A) in the final model
(P 5 .001). There was a trend toward the year of
SCT affecting EFS in univariate analysis (P 5 .07)
with patients undergoing SCT from 1997-2007 having
a superior outcome to those undergoing SCT from
1986-1996 (Figure 4A). However, the year of SCT
was not significant for EFS in the multivariate analysis.
Prognostic Factors for Relapse and NRM
IPSS poor-risk cytogenetics (P 5 .001), and the
FAB subgroup (Figure 3B, P5 .009) were the only var-
iables found to have a significant impact on ROR in
univariate analysis (Table 3), and these 2 factors main-
tained their significance in the multivariate model
(Table 4). In addition, multivariate analysis showed
that non-CR1 status was predictive for post-SCT
relapse (P 5 .04). Univariate analysis with respect to
NRM confirmed the negative influence of a long
interval from diagnosis to SCT (P\ .001), use of an
Table 3. Univariate Analysis for Outcome at 7 Years
Characteristic No. of Pts
EFS Relapse NRM
% P value % P value % P value
IPSS karyotype
Good/intermediate 104 46 .001 17 .004 37 .78
Poor 50 17 38 44
Disease status
CR1 24 67 .004 13 .16 22 .07
Other 132 31 27 43
Interval (Dx/SCT)* 156 — .01 — .14 — <.001
Grade $ II aGVHD
Yes 91 33 .02 16 NE 51 NE
No 65 38 34 28
Stem cell source
Bone marrow 114 33 .07 25 .78 42 .15
Blood 42 45 23 32
Year of SCT
1985-1990 31 26 .07 32 .13 42 .03
1991-1996 46 33 13 54
1997-2001 39 46 23 31
2002-2007 40 45 27 29
FAB diagnosis
RA/RARS/CMML 39 53 4 44
RAEB 31 23 .14 32 .009 42 .72
RAEBIT/sAML 86 32 29 36
Conditioning
Busulfan based 92 37 .28 29 .06 33 .02
TBI based 64 38 17 50
Donor type
Related 88 37 .15 30 .06 32 .007
Unrelated 68 35 17 54
Chronic GVHD
Yes 88 53 .58 17 NE 28 NE
No 29 17 69 14
Age* 156 — .86 — .58 — .67
Sex
Male 79 35 .86 23 .44 42 .27
Female 77 37 26 36
EFS indicates event-free survival; NRM, nonrelapse mortality; Pts, patients; IPSS, International Prognostic Scoring System [22]; CR1, first compete re-
mission; Dx, diagnosis; SCT, stem cell transplantation; aGVHD, acute graft-versus-host disease; NE, not evaluable; TBI, total body irradiation; FAB,
French-American-British; MDS, myelodysplastic syndrome; AML, acute myelogenous leukemia.
*Analyzed as a continuous variable.
Biol Blood Marrow Transplant 15:205-213, 2009 209SCT in Poor-Risk Karyotype MDSunrelated donor (P 5 .007), TBI-based conditioning
(P 5 .02), and the year of SCT (Figure 4B, P 5 .03).
However, only the use of an unrelated donor (P 5
.046) remained significant in the multivariate model
(Table 4).IPSS Cytogenetic Risk Group and Stem Cell
Source
Because both IPSS cytogenetic risk group and
stem cell source appeared to influence EFS in the uni-
variate analysis, survival was analyzed according to
stem cell source in the good/intermediate-risk and
poor-risk cytogenetic groups. EFS in the good/inter-
mediate-risk karyotype patients (N 5 104) at 7 years
was not significantly different in patients who under-
went BM SCT (46%) when compared to those who
underwent BSC transplantation (50%, P5 .56). How-
ever, EFS for patients with a poor-risk karyotype
(n 5 50) was superior in the BSC group (39%) when
compared to BM recipients (6%; P\ .001). EFS bythe cytogenetic risk group according to stem cell
source is shown in Figure 5a and b. In patients with
a poor-risk karyotype, BSC were associated with
a lower NRM (31% versus 51%) and a reduced ROR
(30% versus 42%) when compared to BM, although
neither reached statistical significance (P 5 .11 and
P 5 .35, respectively).DISCUSSION
Allogeneic SCT has been established as a curative
therapy for patients withMDS over the past 2 decades.
Although SCTwas initially reported to result in a 30%
to 40% EFS, both NRM and relapse were found to be
significant issues in this patient population [2-7]. Ad-
vanced age has consistently been associated with infe-
rior EFS because of an increase in NRM [3,4,6,7], and
the presence of excess blasts has been predictive of in-
creased ROR [3,5-7]. High-risk IPSS score [7,34] and,
more specifically, poor-risk BM karyotype [5,8] have
Table 4. Multivariate Analysis for Outcome following SCT
Variable
Hazard Ratio
(95% Confidence Interval) P Value
EFS
Interval Dx/SCT 1.00 <.001
IPSS cytogenetic group
Good/intermediate-risk 1.00
Poor-risk 2.23 (1.45-3.45) <.001
FAB diagnosis
RAEB ± IT/sAML 1.00 .001
RA/RARS/CMMoL 0.37 (0.20-0.68)
Disease status at SCT
CR1 1.00 .005
Other 2.85 (1.38-5.88)
Acute GVHD
Yes 1.57 (1.02-2.41) .04
No 1.00
Relapse
FAB Diagnosis
RAEB ± IT/sAML 1.00 .002
RA/RARS/CMMoL 0.45 (0.27-0.74)
IPSS cytogenetic group
Good/intermediate risk 1.00 .004
Poor risk 2.60 (1.36-4.97)
Disease status at SCT
CR1 1.00 .04
Other 3.32 (1.04-10.55)
NRM
Use of unrelated donor
Yes 2.37 (1.02-5.54) .046
No 1.00
SCT indicates stem cell transplantation; EFS, event-free survival; Dx,
diagnosis; IPSS, International Prognostic Scoring System; FAB, French-
American-British; RA, refractory anemia; RARS, RA with ringed sidero-
blasts; RAEB, RAwith excess blasts; RAEBIT, RAEB in transition; CMML,
chronic myelomoncytic leukemia; sAML, secondary acute
myeloid leukemia; CR1, first complete remission; GVHD, graft-
versus-host disease; NRM, nonrelapse mortality.
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Figure 3. (A) EFS and (B) probability of relapse following allogeneic
SCT for MDS/sAML according to FAB diagnosis.
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SCT, leading to a less favorable EFS.
The use of blood as an allogeneic stem cell source
has been linked by some investigators to better SCT
outcomes, although concurrent developments in pa-
tient/donor selection and supportive care may well
have contributed to improved results [12,14,15]. The
superior results seen with BSC have been attributed,
in part, to more rapid engraftment, leading to a reduc-
tion in NRM. However, a lower relapse rate with BSC
has also been suggested [14], perhaps secondary to an
associated higher incidence of cGVHD [12,16]. The
patients who have appeared to benefit the most from
BSC were those individuals with more advanced dis-
ease, including patients with MDS [14,15] .
Russell et al. [35] initially compared the results of
BSC and BM SCT for high-risk MDS and AML pa-
tients. Although engraftment was faster and cGVHD
more frequent in the BSC group, NRM and relapse
rates were similar with survival being poor in both
BSC and BM patients. Subsequently, an EBMT regis-
try study compared the outcomes of 132 BM and 102
BSC matched sibling transplants for MDS [36]. De-
spite faster engraftment, the BSC patients had a higher
early NRM because of an increased incidence ofaGVHD. However, relapse was significantly lower
with BSC (13% versus 38% with BM), leading to a su-
perior EFS (50% versus 39%, respectively). Of inter-
est, patients with a poor-risk karyotype did not fair
better with BSC than with BM in this registry analysis.
Instead, BSC were found to be most beneficial in ad-
vanced MDS, especially if the recipient was not in
CR at SCT. A similar improved outcome for advanced
MDS patients receiving BSC has also been reported in
a Spanish Registry study [37].
The Seattle group reported on the use of targeted
Bu conditioning in 109 MDS patients who underwent
SCT, 95% of whom had not received prior conven-
tional chemotherapy [8]. The 3-year relapse-free sur-
vival (RFS) was 58%, with a 13% ROR and an NRM
of 29%. Although the only factor that predicted for
an inferior RFS in multivariate analysis was therapy-
related (versus primary) MDS, advanced MDS and
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Figure 4. (A) EFS and (B) NRM according to year of allogeneic SCT for
patients with MDS/sAML.
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Figure 5. EFS following allogeneic BM and blood (PB) SCT for MDS/
sAML and (A) good- or intermediate-risk karytoype and (B) poor-risk
karyotype.
Biol Blood Marrow Transplant 15:205-213, 2009 211SCT in Poor-Risk Karyotype MDSa poor-risk karyotype were both associated with
a higher ROR. Moreover, there was a trend toward
an improved RFS with BSC transplantation (68% ver-
sus 48% with BM SCT), regardless of disease stage.
The results of our current analysis do support that
SCT results are improving for MDS patients at our in-
stitution. The reasons for the superior outcome over
the past decade are likely complex. More rapid referral
of MDS patients for SCT assessment, selection of pa-
tients more likely to benefit from high-dose therapy,
and advances in supportive care, including the use of
mobilized BSC as a stem cell source, may all be con-
tributing to improved survival rates. The use of i.v.
Bu, cytomegalovirus (CMV) screening and preemptive
antiviral therapy, and the development of new antifun-
gal agents could also have had an impact onNRMover
the past decade. Furthermore, DNA-based tissue typ-
ing in the unrelated donor SCT setting has probably
led to a reduced incidence of GVHD. However, de-
spite these advancements in allogeneic SCT, the year
of SCT was not statistically significant in the multivar-
iate analysis for either EFS or NRM.
Although our institutional experience has previ-
ously highlighted the importance of IPSS cytogenetic
group as a risk factor for a higher relapse rate and an
inferior survival following SCT for MDS [5], anintriguing finding in the current study was that pa-
tients with a poor-risk karyotype seemed to particu-
larly benefit from the use of BSC. Patients with
unfavorable cytogenetics had a superior EFS with
BSC compared to BM (39% versus 6%, P\ .001). It
should be acknowledged that there were confounding
differences in characteristics between the BSC and BM
groups, including fewer patients with advanced disease
and a smaller proportion of unrelated recipients in the
BSC group, although the BM cohort was significantly
younger. Nonetheless, a reduction in NRM and
a lower ROR were both noted with the use of BSC, al-
though neither reached statistical significance. This
lack of significance may simply relate to the relatively
small number of patients in the BSC group. Certainly,
we did observe a high incidence of cGVHD in the BSC
group (90%), a development that may be associated
with a reduced ROR but the incidence of cGVHD
was high in the BM group as well (84%, P5 .30), likely
reflecting the significant proportion of unrelated do-
nor recipients (46%) in the BM group.
The use of BSC in unrelated donor SCT was first
evaluated by a retrospective matched pair analysis
comparing BSC and BM [38]. Not surprisingly,
212 Biol Blood Marrow Transplant 15:205-213, 2009T. J. Nevill et al.engraftment was faster with BSC, although no signifi-
cant difference was seen in the 2 groups with regard to
cumulative risk of aGVHD and cGVHD, NRM, re-
lapse, or survival. Subsequent studies have suggested
that BSC may result in a superior EFS in chronic my-
elogenous leukemia (CML) [39] but an inferior EFS in
acute lymphoblastic leukemia (ALL) [18]. A more re-
cent registry analysis showed that BSC are associated
with a higher incidence of aGVHD and cGVHD fol-
lowing unrelated SCT, although EFS was similar re-
gardless of stem cell source [19]. Although only 16
patients in our study received BSC from an unrelated
donor, the results in this subgroup were satisfactory
(6 survivors), suggesting BSC may be a reasonable
choice in MDS patients lacking a family donor.
Although outcomes may be improving for MDS
patients following allogeneic SCT, there remains sig-
nificant room for improvement. NRM and relapse
continue to limit EFS, and there is some controversy
as to whether pre-SCT chemotherapy can reduce the
risk of relapse. It has been reported that excess blasts
at the time of SCT predicts for an increased ROR
[3,5-7], and that attainment of CR prior to SCT can
reduce the risk of post-SCT relapse [40]. However,
others have argued that EFS with allogeneic SCT in
advanced MDS is similar regardless of whether pa-
tients are given standard induction chemotherapy
prior to commencing SCT conditioning [41].
An increasingly popular way to reduce the high
NRM rate associated with SCT is to use a reduced-in-
tensity conditioning regimen (RICT). Martino et al.
[42] reported on 37 patients who underwent RICT
for advanced MDS/AML. Although the incidence of
aGVHD and NRM were low, progression of disease
was common in patients who did not develop cGVHD.
Other studies have supported that RICT leads to lower
NRM but a higher risk of relapse, especially in those
patients not in CR at SCT, resulting in no survival ad-
vantage [43-46]. Furthermore, patients with a poor-
risk karyotype appear to do significantly worse with
RICT [45,46]. Although an impressive 3-year dis-
ease-free survival (DFS) of 41% has been reported us-
ing FBC conditioning prior to unrelated donor blood
SCT inMDS [47], 90% of the patients in this study did
not have excess blasts at the time of SCT and patients
with an intermediate-2 or high-risk IPSS scores did
significantly worse.
Allogeneic SCT is the only known therapy associ-
ated with long-term EFS in patients with MDS, and
outcomes appear to be improving. IPSS poor-risk
karyotype remains a powerful predictor of relapse
and survival, although the development of blood
SCT may lead to superior results in this high-risk
patient subgroup. If this benefit can be confirmed in
larger studies, allogeneic blood SCT could offer cura-
tive potential to an increasing number of patients with
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